5 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 32 points (0.2%) at 14,286 as of Wednesday, March 6, 2013, 11:50 AM ET. The NYSE advances/declines ratio sits at 1,509 issues advancing vs. 1,334 declining with 158 unchanged.

The Health Care sector currently sits up 0.3% versus the S&P 500, which is up 0.1%. Top gainers within the sector include Vertex Pharmaceuticals ( VRTX), up 2.2%, Aetna ( AET), up 1.9%, Celgene Corporation ( CELG), up 1.6%, Teva Pharmaceutical Industries ( TEVA), up 1.4% and Regeneron Pharmaceuticals ( REGN), up 0.8%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector lower today. As of noon trading, Novo Nordisk A/S is down $3.42 (-1.9%) to $178.22 on heavy volume Thus far, 303,704 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 305,900 shares. The stock has ranged in price between $178.22-$180.66 after having opened the day at $180.25 as compared to the previous trading day's close of $181.64.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $101.6 billion and is part of the drugs industry. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 11.3% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Novo Nordisk A/S Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

4. As of noon trading, AstraZeneca ( AZN) is down $0.27 (-0.6%) to $45.75 on light volume Thus far, 590,858 shares of AstraZeneca exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $45.65-$46.05 after having opened the day at $45.95 as compared to the previous trading day's close of $46.02.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases worldwide. AstraZeneca has a market cap of $57.5 billion and is part of the drugs industry. The company has a P/E ratio of 6.3, below the S&P 500 P/E ratio of 17.7. Shares are down 2.6% year to date as of the close of trading on Tuesday. Currently there is 1 analyst that rates AstraZeneca a buy, 3 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, growth in earnings per share, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full AstraZeneca Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

3. As of noon trading, Valeant Pharmaceuticals International ( VRX) is down $0.98 (-1.4%) to $68.81 on light volume Thus far, 371,054 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $68.79-$70.25 after having opened the day at $70.16 as compared to the previous trading day's close of $69.79.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $21.2 billion and is part of the drugs industry. Shares are up 16.8% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and deteriorating net income. Get the full Valeant Pharmaceuticals International Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Life Technologies ( LIFE) is down $0.72 (-1.2%) to $61.03 on light volume Thus far, 845,242 shares of Life Technologies exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $60.69-$62.34 after having opened the day at $61.41 as compared to the previous trading day's close of $61.75.

Life Technologies Corporation operates as a global life sciences company. Life Technologies has a market cap of $10.2 billion and is part of the health services industry. The company has a P/E ratio of 24.9, above the S&P 500 P/E ratio of 17.7. Shares are up 25.9% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Life Technologies a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Life Technologies as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Life Technologies Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Eli Lilly and Company ( LLY) is down $0.50 (-0.9%) to $55.04 on light volume Thus far, 2.5 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 7.0 million shares. The stock has ranged in price between $54.92-$55.67 after having opened the day at $55.60 as compared to the previous trading day's close of $55.54.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $62.1 billion and is part of the drugs industry. The company has a P/E ratio of 15.0, below the S&P 500 P/E ratio of 17.7. Shares are up 12.6% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 4 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Company Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade